Skip to content
DataLookout
Menu

PAUSENCT07945652

Portable Absence Seizure Detection Using Smart Earbuds

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Sensitivity (Recall)
Timeframe: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
Precision
Timeframe: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
F1-score
Timeframe: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)
False Alarm Rate in 24 hours
Timeframe: 1 day, during simultaneous use of the IMD and 25-channel scalp EEG (in-hospital phase)

Secondary (3)

Signal quality
Usability Scores
Data Yield

Arms and interventions

Absence patients

Adults and children with idiopathic generalized epilepsy syndromes, i.e., Childhood Absence Epilepsy, Juvenile Absence Epilepsy, and Juvenile Myoclonic Epilepsy, with active disease and having typical absences. Prospective, single-center, open-label, comparative diagnostic accuracy study. Study participants will be contacted during the screening phase based on the scheduled admission for 24-hour vEEG in the epilepsy monitoring units of UZ Leuven. After screening and signing the IFC, they will be asked to come to the hospital for ear-mold imprinting. These prints will serve as the basis for customizing the headset. The study will employ a hybrid design, consisting of two phases: Phase A (In-Hospital Validation: participants will wear the IMD simultaneously with the standard 10-20 scalp EEG montage. This provides the ground truth labels for validation. Phase B (At home): participants will wear the device at least once a week for 3 weeks to assess real-world usability